001     164533
005     20240722121854.0
024 7 _ |a 10.1002/ana.26416
|2 doi
024 7 _ |a pmid:35599344
|2 pmid
024 7 _ |a 0364-5134
|2 ISSN
024 7 _ |a 1531-8249
|2 ISSN
024 7 _ |a altmetric:128772172
|2 altmetric
037 _ _ |a DZNE-2022-01082
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Liu, Hui
|0 P:(DE-2719)9001971
|b 0
|e First author
245 _ _ |a Polygenic resilience modulates the penetrance of Parkinson's disease genetic risk factors.
260 _ _ |a Hoboken, NJ
|c 2022
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1721637037_12031
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a CC BY-NC-ND
520 _ _ |a The aim of the current study is to understand why some individuals avoid developing Parkinson's disease (PD) in spite of being at relatively high genetic risk, using the largest datasets of individual-level genetic data available.We calculated polygenic risk score to identify controls and matched PD cases with the highest burden of genetic risk for PD in the discovery cohort (IPDGC, 7,204 PD cases and 9,412 controls) and validation cohorts (COURAGE-PD, 8,968 cases and 7,598 controls; UKBB, 2,639 PD cases and 14,301 controls; AMP-PD, 2,248 cases and 2,817 controls). A genome-wide association study meta-analysis was performed on these individuals to understand genetic variation associated with resistance to disease. We further constructed a polygenic resilience score, performed MAGMA gene-based analyses and functional enrichment analyses.A higher polygenic resilience score was associated with a lower risk for PD (Beta= -0.054, SE = 0.022; P = 0.013). Although no single locus reached genome-wide significance, MAGMA gene-based analyses nominated TBCA as a putative gene. Furthermore, we estimated the narrow-sense heritability associated with resilience to PD (h2 = 0.081, SE = 0.035, P = 0.0003). Subsequent functional enrichment analysis highlighted histone methylation as potential pathway harboring resilience alleles that could mitigate the effects of PD risk loci.The present study represents a novel and comprehensive assessment of heritable genetic variation contributing to PD resistance. We show that a genetic resilience score can modify the penetrance of PD genetic risk factors and therefore protect individuals carrying a high-risk genetic burden from developing PD. This article is protected by copyright. All rights reserved.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Parkinson's disease
|2 Other
650 _ 7 |a genetics
|2 Other
650 _ 7 |a polygenic risk
|2 Other
650 _ 7 |a resilience
|2 Other
700 1 _ |a Dehestani, Mohammad
|0 P:(DE-2719)9002232
|b 1
|u dzne
700 1 _ |a Blauwendraat, Cornelis
|0 P:(DE-2719)2810837
|b 2
700 1 _ |a Makarious, Mary B
|b 3
700 1 _ |a Leonard, Hampton L
|0 P:(DE-2719)9001970
|b 4
700 1 _ |a Kim, Jonggeol J
|b 5
700 1 _ |a Schulte, Claudia
|0 P:(DE-2719)9000366
|b 6
700 1 _ |a Noyce, Alastair
|0 0000-0003-3027-5497
|b 7
700 1 _ |a Jacobs, Benjamin M
|b 8
700 1 _ |a Foote, Isabelle
|0 0000-0002-0253-4116
|b 9
700 1 _ |a Sharma, Manu
|0 P:(DE-2719)9000296
|b 10
700 1 _ |a Consortium, International Parkinson's Disease Genomics
|b 11
|e Collaboration Author
700 1 _ |a Genetics, Comprehensive Unbiased Risk factor Assessment for
|b 12
700 1 _ |a Disease, Environment in Parkinson's
|b 13
|e Collaboration Author
700 1 _ |a Nalls, Mike
|b 14
700 1 _ |a Singleton, Andrew
|b 15
700 1 _ |a Gasser, Thomas
|0 P:(DE-2719)2320009
|b 16
700 1 _ |a Bandres-Ciga, Sara
|b 17
773 _ _ |a 10.1002/ana.26416
|g p. ana.26416
|0 PERI:(DE-600)2037912-2
|n 2
|p 270-278
|t Annals of neurology
|v 92
|y 2022
|x 0364-5134
856 4 _ |u https://pub.dzne.de/record/164533/files/DZNE-2022-01082.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/164533/files/DZNE-2022-01082.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:164533
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9001971
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9002232
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 2
|6 P:(DE-2719)2810837
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 4
|6 P:(DE-2719)9001970
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)9000366
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)9000296
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 16
|6 P:(DE-2719)2320009
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-30
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ANN NEUROL : 2021
|d 2022-11-30
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ANN NEUROL : 2021
|d 2022-11-30
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2021-02-03
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-30
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-30
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-30
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-30
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-30
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 0
920 1 _ |0 I:(DE-2719)6000018
|k Tübingen common
|l Tübingen common
|x 1
920 1 _ |0 I:(DE-2719)5000057
|k Ext HIH
|l Ext Hertie-Institut für klinische Hirnforschung
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)6000018
980 _ _ |a I:(DE-2719)5000057
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21